STOCK TITAN

Semler Scientific, Inc. - SMLR STOCK NEWS

Welcome to our dedicated page for Semler Scientific news (Ticker: SMLR), a resource for investors and traders seeking the latest updates and insights on Semler Scientific stock.

Semler Scientific, Inc. (Nasdaq: SMLR) is an innovative medical risk-assessment company focused on developing, manufacturing, and marketing diagnostic and testing products that enhance patient care while bridging the gap between the cost of care and its compensation. Listed on Nasdaq since February 26, 2014, Semler operates primarily in the United States, offering proprietary technology solutions that improve clinical effectiveness and efficiency for healthcare providers, insurance plans, and risk assessment groups.

Semler's flagship product, QuantaFlo®, is a rapid, in-office test for measuring arterial blood flow in the extremities. This four-minute test aids in diagnosing peripheral arterial disease (PAD) and heart dysfunction (HD). QuantaFlo® is FDA-cleared and is employed by healthcare providers to evaluate patients' risks of mortality and major adverse cardiovascular events (MACE).

Beyond QuantaFlo®, Semler Scientific has made strategic alliances and investments to expand its product portfolio. The company has an exclusive marketing and distribution agreement with Mellitus Health, Inc. for Insulin Insights™, an FDA-cleared software product that recommends optimal insulin dosing for diabetic patients. Additionally, Semler holds minority investments in Mellitus, Monarch Medical Technologies LLC (developer of EndoTool® for inpatient glycemic management), and SYNAPS Dx.

In the latest financial results for Q3 2023, Semler reported consistent growth in quarterly revenue and pre-tax net income, predominantly from QuantaFlo® sales. The company continues to focus on expanding its business into heart dysfunction diagnosis.

Semler has also recently adopted Bitcoin as its primary treasury reserve asset, reflecting a strategic move to leverage the digital currency for long-term value and as a hedge against inflation. As of June 6, 2024, the company holds 828 bitcoins, underscoring its commitment to this innovative investment strategy.

More detailed information about Semler Scientific, its products, and investment strategies can be found on their website.

Rhea-AI Summary

Semler Scientific (Nasdaq: SMLR) has announced the purchase of an additional 83 bitcoins for $5.0 million in cash, including fees and expenses. As of August 26, 2024, the company now holds a total of 1,012 bitcoins, acquired for a cumulative $68.0 million. Eric Semler, chairman of Semler Scientific, stated that the purchase was made using primarily cash from operations and capital raised through their at-the-market equity program.

The company expressed optimism about the growing institutional adoption of bitcoin, noting that institutions now own more than 20% of bitcoin ETF assets under management. Semler believes this increasing institutionalization will drive value for both bitcoin prices and their stockholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
Rhea-AI Summary

Semler Scientific (NASDAQ: SMLR) reported Q2 2024 financial results and additional Bitcoin purchases. Key points:

  • Revenues decreased 22% to $14.5 million
  • Income from operations fell 25% to $5.4 million
  • Net income dropped to $11,000 from $5.9 million in Q2 2023
  • Purchased 929 bitcoins for $63 million total
  • Bitcoin holdings fair value of $54.9 million as of June 30, reflecting $5.1 million reduction

The company remains focused on acquiring Bitcoin while supporting its healthcare business. Semler plans to purchase more Bitcoin using cash from operations and potentially from selling securities under a $150 million shelf registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
-
Rhea-AI Summary

Semler Scientific (Nasdaq: SMLR), a company focused on developing technology solutions for chronic disease management in healthcare, has announced its plans to report financial results for Q2 and H1 2024 on August 5, 2024, after U.S. market close. The company will host a conference call at 4:30 pm ET on the same day, led by CEO Doug Murphy-Chutorian, with participation from Chairman Eric Semler, CFO Renae Cormier, and COO Jennifer Oliva-Herrington.

Investors are encouraged to submit questions in advance to ir@semlerscientific.com and pre-register for the call. Those unable to pre-register can dial in using provided domestic and international numbers. The call will be archived on Semler Scientific's website for future reference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
conferences earnings
Rhea-AI Summary

Semler Scientific announced the purchase of an additional 247 bitcoins for $17 million in cash, including fees and expenses. This brings their total bitcoin holdings to 828, acquired for $57 million. CEO Doug Murphy-Chutorian emphasized their dual strategy of expanding their healthcare business and investing in bitcoin, viewing it as a reliable store of value. As of June 6, 2024, the company continues to focus on these strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.58%
Tags
none
-
Rhea-AI Summary

Semler Scientific (Nasdaq: SMLR) has adopted bitcoin as its primary treasury reserve asset, purchasing 581 bitcoins for $40 million. Chairman Eric Semler stated that bitcoin's scarcity and digital resilience make it a superior store of value and a potential hedge against inflation compared to gold. The SEC's approval of bitcoin exchange-traded funds and institutional investments validate this strategy. Despite the bitcoin focus, Semler will continue prioritizing its core medical products, particularly QuantaFlo® for peripheral arterial disease testing, while seeking FDA clearance for expanded labeling. Bitcoin holdings will be subject to market conditions and cash needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.36%
Tags
none
-
Rhea-AI Summary

Semler Scientific, Inc. reported $15.9 million in revenue for the first quarter of 2024, a 13% decrease from the same period in 2023. Net income increased by 22% to $6.1 million. The company's cash balance rose to $62.9 million. Despite revenue decline from the PAD product, the CEO remains optimistic about future revenue growth pending FDA clearance for a new product. Semler Scientific also achieved year-over-year net income growth and a record cash balance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.29%
Tags
Rhea-AI Summary
Semler Scientific, Inc. (Nasdaq: SMLR) will report Q1 financial results on May 7, 2024. The call will be hosted by CEO Doug Murphy-Chutorian, along with CFO Renae Cormier and COO Jennifer Oliva-Herrington. Participants can pre-register for the conference call to receive immediate access details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
conferences earnings
-
Rhea-AI Summary
Semler Scientific, Inc. (SMLR) reports strong financial results for Q4 and full year 2023 with revenue and net income growth. The company's focus on QuantaFlo® boosts sales. Key figures include Q4 revenues of $15.1 million, a 9% increase, and full year revenues of $68.2 million, a 20% rise. Net income for Q4 was $4.2 million, up by 31%, and full year net income reached $20.6 million, a 44% increase. Cash balance grew to $57.3 million. The company plans to seek FDA clearance for expanded product use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.89%
Tags
-
Rhea-AI Summary
Semler Scientific, Inc. (SMLR) will report financial results for Q4 and full year 2023 on March 5, 2024. The CEO will host a conference call with the CFO and COO. Participants can pre-register for the call. Internet and phone dial-in options are available for joining the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
conferences earnings
Rhea-AI Summary
Semler Scientific, Inc. (Nasdaq: SMLR) reported Q3 2023 highlights, including revenue of $16.3 million, a 16% increase from 2022, and net income of $5.5 million, a 50% increase from 2022. The company also reported quarter-ending cash, cash equivalents, and short-term investments of $56.0 million. Major accomplishments include continued year-over-year quarterly revenue growth and pre-tax net income growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.03%
Tags

FAQ

What is the current stock price of Semler Scientific (SMLR)?

The current stock price of Semler Scientific (SMLR) is $52.3 as of January 28, 2025.

What is the market cap of Semler Scientific (SMLR)?

The market cap of Semler Scientific (SMLR) is approximately 494.1M.

What does Semler Scientific, Inc. do?

Semler Scientific develops, manufactures, and markets diagnostic and testing products that assist healthcare providers in evaluating and treating chronic diseases.

What is QuantaFlo®?

QuantaFlo® is Semler's flagship product, an FDA-cleared, rapid point-of-care test that measures arterial blood flow in the extremities, aiding in the diagnosis of cardiovascular diseases such as PAD and heart dysfunction.

When did Semler Scientific go public?

Semler Scientific went public on February 26, 2014, and its common stock is listed on Nasdaq under the ticker symbol SMLR.

What recent achievements has Semler Scientific made?

Semler has reported consistent growth in revenue, expanded its product offerings through strategic investments and partnerships, and adopted Bitcoin as its primary treasury reserve asset.

What is Insulin Insights™?

Insulin Insights™ is an FDA-cleared software product developed by Mellitus Health, Inc., which Semler Scientific exclusively markets. It recommends optimal insulin dosing for diabetic patients.

How is Semler Scientific involved with Bitcoin?

Semler Scientific has adopted Bitcoin as its primary treasury reserve asset and has purchased a substantial number of bitcoins as part of its investment strategy.

Who are Semler Scientific’s primary customers?

Semler's customers include insurance plans, physicians, and risk assessment groups who use its products to evaluate and treat chronic diseases.

Where is Semler Scientific headquartered?

Semler Scientific is headquartered in Santa Clara, California, USA.

What other companies is Semler Scientific invested in?

Semler has minority investments in Mellitus Health, Inc., Monarch Medical Technologies LLC, and SYNAPS Dx.

What is the financial outlook for Semler Scientific?

Semler continues to report strong financial performance, with consistent growth in revenue and pre-tax net income, primarily driven by sales of its QuantaFlo® product.
Semler Scientific, Inc.

Nasdaq:SMLR

SMLR Rankings

SMLR Stock Data

494.05M
7.51M
17.29%
43.68%
14.22%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
SANTA CLARA